{
  "docId": "019de074-ca9a-70d9-9ba2-1d5f94361fe0",
  "docSlug": "6d754588aa25b32079af055d51113b03",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 38,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 12,
  "notes": "The slide presents a standard quarterly financial comparison (P&L summary) and balance sheet highlights.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ca9a-70d9-9ba2-1d5f94361fe0/23",
  "deckHref": "/decks/019de074-ca9a-70d9-9ba2-1d5f94361fe0",
  "deckJsonHref": "/decks/019de074-ca9a-70d9-9ba2-1d5f94361fe0.json",
  "deckAnchorHref": "/decks/019de074-ca9a-70d9-9ba2-1d5f94361fe0#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.075,
        "w": 0.785,
        "x": 0.068,
        "y": 0.183
      },
      "kind": "paragraph",
      "text": "Cash and cash equivalents, marketable securities and restricted cash as of March 31, 2022: $39.8¹ million (no debt)\nAs of March 31, 2023, 94.3 million² common shares and pre-funded warrants outstanding",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d202a7d-5825-4686-a1f8-716b28b6ef1f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.068,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "¹ Includes $1.3mm of restricted cash. ²Includes 65.4 million common shares outstanding and 28.9 million pre-funded warrants.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "328ba677-2c6f-42b2-bc19-8df738c7380c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.66,
        "x": 0.17,
        "y": 0.404
      },
      "kind": "table",
      "text": "Revenue, R&D Expense, G&A Expense, Net Loss for 3/31/23 and 3/31/22",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a26b43b-47fd-4ae1-b392-78d69d195e60",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.088,
        "w": 0.298,
        "x": 0.068,
        "y": 0.038
      },
      "kind": "title",
      "text": "Financial Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ed93d66-b694-47a3-a461-3c44570e3c82",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 38,
      "from": 3,
      "beatId": "e469074b-5500-4414-8b81-ef0652ee8a7d",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 3-38 present various traction metrics, including clinical trial results and financial summaries",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}